Activation of RyR2 by class I kinase inhibitors.

A D ChakrabortyL A GonanoM L MunroL J SmithC ThekkedamV StaudacherA B GambleN MacquaideA F DulhuntyPeter P Jones

Published in: British journal of pharmacology (2019)

Part of the cardiotoxicity of class I kinase inhibitors can be assigned to their effect on RyR2 and increase in SOICR. Compounds with anti-SOICR activity may represent an improved treatment option for patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors